Spots Global Cancer Trial Database for anthracyclines
Every month we try and update this database with for anthracyclines cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cardiac Dysfunction in Childhood Cancer Survivors | NCT03790943 | Cardiac Dysfunc... Cardiovascular ... Childhood Cance... | cardiac assessm... | 18 Years - | University of Bern | |
| A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines | NCT00548704 | Extravasation | Dexrazoxane | 18 Years - | Valerio Therapeutics | |
| Resistance and Aerobic Exercise for Subclinical Anthracycline Cardiomyopathy | NCT01071473 | Cardiomyopathy | 12 Week Exercis... | 18 Years - | St. Jude Children's Research Hospital | |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | NCT00111345 | Myeloid Leukemi... | Anthracyclines liposomal dauno... 2-CDA AI | 1 Day - 18 Years | University Hospital Muenster | |
| Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML | NCT05703126 | Acute Myeloid L... Cardiotoxicity Endothelial Dys... | History taking Anthropometry Complete blood ... Biochemical blo... Coagulogram Immunoenzymatic... Stress echocard... Triplex scannin... Electrocardiogr... Ultrasound of t... Cytogenetic exa... Cytological exa... Immunophenotypi... Determination o... laser Doppler f... | 18 Years - 65 Years | Samara State Medical University | |
| 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia | NCT01587430 | Acute Myeloid L... | high dose ARA-C standard dose A... | 15 Years - 60 Years | National Research Center for Hematology, Russia | |
| Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2) | NCT03748550 | Cancer, Breast Cardiotoxicity Cardiovascular ... | Aerobic exercis... | 18 Years - | Nova Scotia Health Authority | |
| 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia | NCT01587430 | Acute Myeloid L... | high dose ARA-C standard dose A... | 15 Years - 60 Years | National Research Center for Hematology, Russia | |
| Investigating Cardiovascular Adverse Events Related to Cancer Treatment | NCT03199300 | Toxicity Due to... Cardiovascular ... Cancer, Treatme... | Anthracyclines Trastuzumab Cisplatin Bleomycin | 18 Years - | University Medical Center Groningen | |
| Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer | NCT02065908 | Breast Cancer | 18 Years - 70 Years | West Pomeranian Cancer Center | ||
| Cardioprotective Effect of Acute Exercise in Breast Cancer Patients | NCT05467111 | Early-stage Bre... | Acute Exercise | 18 Years - | Technical University of Madrid | |
| Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients | NCT05732051 | Breast Cancer Metastatic Brea... Cancer Therapy-... Cardiotoxicity Heart Failure | Nicotinamide Ri... Placebo | 18 Years - | University Hospital, Akershus | |
| Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study | NCT03850171 | Breast Neoplasm... Lymphoma Cardiotoxicity Anthracyclines Physical Activi... | Exercise Traini... | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG | NCT04892667 | Lymphoma, Non-H... Lymphoma, Hodgk... | intervention | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2) | NCT03748550 | Cancer, Breast Cardiotoxicity Cardiovascular ... | Aerobic exercis... | 18 Years - | Nova Scotia Health Authority | |
| Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab | NCT02236806 | Breast Cancer Cardiotoxicity | Bisoprolol Ramipril Placebo | 18 Years - | Azienda Ospedaliero-Universitaria Careggi | |
| Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer | NCT02506361 | Breast Cancer | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | ||
| Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR) | NCT00679874 | Breast Cancer | Cardio-vascular... | - | University of Calgary | |
| Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy | NCT04939883 | Cancer | Carvedilol Placebo | 18 Years - | Hospital Sirio-Libanes | |
| Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX) | NCT06005259 | Cardiotoxicity Neoplasms Chemotherapy Ef... Heart Failure | Spironolactone Placebo | 18 Years - | University of Sao Paulo | |
| Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG | NCT04892667 | Lymphoma, Non-H... Lymphoma, Hodgk... | intervention | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines | NCT00548704 | Extravasation | Dexrazoxane | 18 Years - | Valerio Therapeutics | |
| Prevention of Anthracycline-induced Cardiotoxicity | NCT01968200 | Cancer | Enalapril | 18 Years - | European Institute of Oncology | |
| Cardiac Dysfunction in Childhood Cancer Survivors | NCT03790943 | Cardiac Dysfunc... Cardiovascular ... Childhood Cance... | cardiac assessm... | 18 Years - | University of Bern | |
| Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines | NCT00548561 | Anthracycline E... | Dexrazoxane | 18 Years - | Valerio Therapeutics | |
| Magnetic Resonance Imaging:A Window to Anthracycline Toxicity | NCT03211520 | Cardiac Complic... | 9 Years - 18 Years | Connecticut Children's Medical Center | ||
| Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors | NCT02485626 | Breast Neoplasm... Cardiovascular ... | 2D tissue doppl... | 40 Years - 50 Years | The Netherlands Cancer Institute | |
| Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines | NCT05271162 | Cardiotoxicity | Empagliflozin 1... Placebo | 18 Years - | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years | NCT00563953 | Breast Cancer | Liposomal pegyl... | 18 Years - | SOLTI Breast Cancer Research Group | |
| Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT00344422 | Multiple Myelom... Myeloma M-Protein Myeloma Protein... | Vincristine, DO... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab | NCT02236806 | Breast Cancer Cardiotoxicity | Bisoprolol Ramipril Placebo | 18 Years - | Azienda Ospedaliero-Universitaria Careggi | |
| Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors | NCT02485626 | Breast Neoplasm... Cardiovascular ... | 2D tissue doppl... | 40 Years - 50 Years | The Netherlands Cancer Institute | |
| Pharmacokinetic Study of Doxorubicin in Children With Cancer | NCT01095926 | Wilms Tumor Neuroblastoma Soft Tissue Sar... Acute Lymphobla... | doxorubicin | - 17 Years | University Hospital Muenster | |
| CardioPROTECTion With Dapagliflozin in Breast Cancer Patients Treated With AnthrAcycline - PROTECTAA TRIAL | NCT06304857 | Breast Cancer Heart Failure | Dapagliflozin Placebo | 18 Years - 80 Years | 4th Military Clinical Hospital with Polyclinic, Poland | |
| Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG | NCT04892667 | Lymphoma, Non-H... Lymphoma, Hodgk... | intervention | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents | NCT01596088 | Extravasations ... | Dexrazoxane | 20 Years - | Kissei Pharmaceutical Co., Ltd. | |
| Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT00344422 | Multiple Myelom... Myeloma M-Protein Myeloma Protein... | Vincristine, DO... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity | NCT03964142 | Cardiotoxicity Cardiac Rehabil... | Cardiac rehabil... | 18 Years - 69 Years | Hospital Clinico Universitario de Santiago | |
| Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity | NCT03964142 | Cardiotoxicity Cardiac Rehabil... | Cardiac rehabil... | 18 Years - 69 Years | Hospital Clinico Universitario de Santiago | |
| Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects | NCT03131024 | Breast Cancer F... | 50% caloric res... Aerobic exercis... | 18 Years - | University of Alberta | |
| Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer | NCT02506361 | Breast Cancer | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | ||
| Stem Cell Injection in Cancer Survivors | NCT02509156 | Cardiomyopathy ... | Allo-MSCs Placebo | 18 Years - 79 Years | The University of Texas Health Science Center, Houston |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
